cintredekin besudotox
Recombinant proteinexperimental
Clinical trial activity
12 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
6
Phase 3
1
Phase 4
0
Earliest trial started Oct 1, 2000 (NCT00006268)
Timeline
Indications
Mechanism of action
- Interleukin-13 receptor subunit alpha-2BINDING AGENT
IL13RA2 binding agent
Cytotoxic. Targets and kills tumor cells that express the IL13 receptor (IL13R).
- Interleukin-13BINDING AGENT
IL13 binding agent
- Interleukin 13 receptorBINDING AGENT
Interleukin 13 receptor binding agent
Cytotoxic. Targets and kills tumor cells that express the IL13 receptor (IL13R).
- Elongation factor 2INHIBITOR
Elongation factor 2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- pseudomonas exotoxin
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108583 ↗
Also known as
- cintredekin besudotox
- cintredekin besudotox
- cintredekin besudotox
- cintredekin besudotox
- il-13-pe
- il13-pe38
- il13-pe38qqr
- il13-pe38qqr
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01832974 | Phase 1 | Dec 1, 2012 | Insys Therapeutics Inc, National Institutes of Health (NIH) |
| NCT00880061 | Phase 1 | Apr 7, 2009 | National Institute of Neurological Disorders and Stroke (NINDS) |
| NCT00378235 | Phase 1/Phase 2 (Phase 2) | Sep 18, 2006 | Insys Therapeutics Inc, St. Jude Children's Hospital, University of California, San Francisco |
| NCT00053040 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2005 | National Cancer Institute (NCI), Pediatric Brain Tumor Consortium, University of California, San Francisco |
| NCT00089427 | Phase 1 | Jul 1, 2004 | Insys Therapeutics Inc |
| NCT00076986 | Phase 3 | Feb 1, 2004 | Insys Therapeutics Inc |
| NCT00064779 | Phase 1 | Jul 1, 2003 | Insys Therapeutics Inc |
| NCT00041587 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2002 | Insys Therapeutics Inc |
| NCT00036972 | Phase 1 | Nov 1, 2001 | Cornell University, National Cancer Institute (NCI) |
| NCT00024557 | Phase 1 | Jun 1, 2001 | Insys Therapeutics Inc |
| NCT00024570 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2000 | Insys Therapeutics Inc, Johns Hopkins University |
| NCT00006268 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2000 | Johns Hopkins University, National Cancer Institute (NCI) |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Insys Therapeutics Inc | For profit | 8 | 8 | 3 | 2000 |
| National Cancer Institute (NCI) | Government | 3 | 1 | 2 | 2000 |
| Johns Hopkins University | Academic/Hospital | 2 | 0 | 1 | 2000 |
| University of California, San Francisco | Academic/Hospital | 2 | 0 | 1 | 2005 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2001 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 1 | 1 | 2009 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2012 |
| Pediatric Brain Tumor Consortium | Academic/Hospital | 1 | 1 | 1 | 2005 |
| St. Jude Children's Hospital | Academic/Hospital | 1 | 0 | 1 | 2006 |
9 organizations
Page 1 / 1